Q: On Oct 1, Beam Therapeutics announced an equity offering priced at $23.50/share; over the following days, the share price declined to as low as $22.24, i.e., below the offering price, though not as low as would reflect the dilutive effect of the new shares.
Yet today shares traded as high as $34.38; what, if anything, can we infer from this disconnect? Who would pay so much when new shares can be had at 2/3 the price?
Yet today shares traded as high as $34.38; what, if anything, can we infer from this disconnect? Who would pay so much when new shares can be had at 2/3 the price?